Thus, the mutant IDH2 inhibitor AG-221 (Enasidenib) and mutant IDH1 inhibitor AG-120 (Ivosidenib) have been extensively investigated for the treatment of patients with AML or MDS with a susceptible IDH mutation. The gene discussed is IDH1; the disease is myelodysplastic syndrome.